Takeda Pharmaceutical (TAK) Research & Development (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Research & Development of -$1.1 billion for Q2 2026, down 5.61% year-over-year from -$1.1 billion in Q2 2025, and down 114.24% quarter-over-quarter from $7.4 billion in Q1 2026.
Takeda Pharmaceutical (TAK) Research & Development (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Research & Development history runs 10 years deep, the most recent figure standing at -$1.1 billion for Q2 2026.
- In Q2 2026, Research & Development fell 5.61% year-over-year to -$1.1 billion; the TTM figure through Jun 2026 stood at $4.1 billion (down 15.95% YoY), while the FY2026 annual figure was $4.5 billion, down 6.33% from the prior year.
- Research & Development for Q2 2026 stood at -$1.1 billion, down from $7.4 billion in the prior quarter.
- The five-year high for Research & Development was $8.5 billion in Q1 2024, with the low at -$1.3 billion in Q3 2023.
- The 5-year median for Research & Development is -$1.1 billion (2024), against an average of $374.8 million.
- The sharpest annual moves came in 2022 and 2024: Research & Development tumbled 116.38% in 2022, then surged 793.43% in 2024.
- Takeda Pharmaceutical's Research & Development stood at -$1.2 billion in 2022, then decreased by 2.56% to -$1.3 billion in 2023, then increased by 11.69% to -$1.1 billion in 2024, then declined by 1.71% to -$1.1 billion in 2025, then increased by 7.76% to -$1.1 billion in 2026.
- Business Quant data shows TAK's Research & Development at -$1.1 billion in Q2 2026, $7.4 billion in Q1 2026, and -$1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 970.00 Mn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | -1.05 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 146.30 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 248.30 Mn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 326.70 Mn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 92.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | - |
| 10 | Alkermes | 8.25 Bn | 7.60 Bn | 397.90 Mn | 154.36 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.05 Bn |
| Mar 31, 2026 | 7.37 Bn |
| Dec 31, 2025 | -1.14 Bn |
| Sep 30, 2025 | -1.10 Bn |
| Jun 30, 2025 | -994.45 Mn |
| Mar 31, 2025 | 8.16 Bn |
| Dec 31, 2024 | -1.12 Bn |
| Sep 30, 2024 | -1.18 Bn |
| Jun 30, 2024 | -1.08 Bn |
| Mar 31, 2024 | 8.53 Bn |
| Dec 31, 2023 | -1.27 Bn |
| Sep 30, 2023 | -1.27 Bn |
| Jun 30, 2023 | -1.19 Bn |
| Mar 31, 2023 | -1.23 Bn |
| Dec 31, 2022 | -1.24 Bn |
| Sep 30, 2022 | -1.12 Bn |
| Jun 30, 2022 | -1.11 Bn |
| Mar 31, 2022 | -1.24 Bn |
| Dec 31, 2021 | -1.13 Bn |
| Sep 30, 2021 | -1.20 Bn |